Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095864 | 0.97 | SIGMAR1 (0.39) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL21573246 | 0.97 | SIGMAR1 (0.39) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL22271217 | 0.97 | SIGMAR1 (0.39) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL27290181 | 0.97 | SIGMAR1 (0.39) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL12717632 | 0.94 | — | — | |
| SCHEMBL16205340 | 0.88 | — | — | |
| SCHEMBL22422691 | 0.87 | SIGMAR1 (0.37) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL22422689 | 0.87 | SIGMAR1 (0.37) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL10997906 | 0.82 | SIGMAR1 (0.36) | SIGMAR1DPP4OPRM1OPRL1PHGDH | |
| SCHEMBL10999201 | 0.81 | DPP4 (0.41) | SIGMAR1DPP4OPRM1OPRL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2020138499-A1 | ALKYL-SUBSTITUTED COMPOUND | 大日本住友製薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| WO-2017045751-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2014037313-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | SIGMAR1 3391/4885DPP4 3640/4885OPRM1 4589/4885 |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | SIGMAR1 3506/4885DPP4 3170/4885OPRM1 3872/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | SIGMAR1 3506/4885DPP4 3170/4885OPRM1 3872/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | SIGMAR1 3506/4885DPP4 3170/4885OPRM1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.